Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AMRI Announces the Promotion of Richard Saffee

Published: Wednesday, January 09, 2013
Last Updated: Wednesday, January 09, 2013
Bookmark and Share
Company promotes Mr. Saffee to Vice President and General Manager of large scale manufacturing.

AMRI has announced that Richard A. Saffee has been promoted to the newly created role of Vice President and General Manager of Large Scale Manufacturing, effective immediately.

He will continue to report to Steven R. Hagen, Ph.D., Senior Vice President of Pharmaceutical Development and Manufacturing.

Mr. Saffee will assume oversight for large scale manufacturing in Aurangabad, India in addition to his current responsibilities for leadership of AMRI’s large scale manufacturing and GMP business in the United States in the Capital Region of New York.

Additionally, Mr. Saffee will work with AMRI’s Holywell, UK site to assist them in their large scale manufacturing business.

Mr. Saffee will be positioned to drive synergies between the locations that will improve quality, efficiency and delivery of world class API’s.

“We are pleased to announce this promotion of Mr. Saffee,” said Dr. Hagen. “Mr. Saffee joined AMRI in 2009 with more than 23 years of industrial and leadership experience in the chemical manufacturing of bulk Active Pharmaceutical Ingredients (API) for both human and animal health. Since joining AMRI, Rick’s leadership has been instrumental in many successes achieved at the Rensselaer large scale manufacturing location. We look forward to his leadership in our continued efforts to achieve closer integration among all of our manufacturing facilities.”

Backed by an excellent compliance history and track record, AMRI’s worldwide manufacturing facilities are equipped for Phase I through commercial API manufacturing.

As a part of AMRI’s SMARTSOURCING™ initiative, this closer integration of facilities under Mr. Saffee provides an added advantage as customers move their compounds from early development to high potency and large scale manufacturing.

These global sites in the United States, Europe and Asia also provide tailored solutions for the biotech and pharma industry, and enable the efficient, cost-effective transfer of products and projects.

AMRI also provides raw materials and starting materials for cGMP manufacturing of API.

Before coming to AMRI, Mr. Saffee led manufacturing activities for multiple U.S.-based operations for Pfizer Global Manufacturing. and Pfizer Global Human Health.

Prior to the acquisition of Parke-Davis by Pfizer, Mr. Saffee held roles of increasing responsibility at Parke-Davis including Director of Chemical Manufacturing and Area Production Manager.

He has extensive knowledge in the areas of chemical manufacturing, technology transfer, regulatory compliance and quality standards, purchasing and materials management and managing global relationships. He is also trained in Lean Six Sigma techniques.

Mr. Saffee earned a Master’s degree in Business Administration from Grand Valley State University in Allendale, Michigan and a Bachelor’s of Science degree in Chemical Engineering from the University of Michigan in Ann Arbor, Michigan.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Wednesday, December 16, 2015
AMRI to Close Holywell, U.K. API Manufacturing Facility
Company plans to cease operations at the site by the end of 2015.
Thursday, April 09, 2015
AMRI Announces CFO Transition
Michael M. Nolan, senior vice president and chief financial officer, will be departing AMRI.
Thursday, January 15, 2015
AMRI To Acquire Aptuit Drug Product Development Businesses
Significantly expands AMRI's analytical services capabilities and extends drug product development services to include sterile injectable formulation development.
Friday, January 09, 2015
AMRI to Acquire Oso Biopharmaceuticals Manufacturing
Acquisition significantly expands contract manufacturing capabilities to include commercial scale sterile injectables.
Tuesday, June 03, 2014
AMRI to Acquire Cedarburg Pharmaceuticals, Inc.
Broadens contract development and manufacturing capabilities with high value, complex API business.
Friday, March 28, 2014
AMRI Announces Senior Level Leadership Appointment
The appointment of Michael A. Luther, Ph.D. as Senior Vice President of Discovery sees AMRI expanding its biology capabilities.
Thursday, October 17, 2013
AMRI Awarded Contract from the UK Government
Seven-year contract awarded for the development and manufacture of an active ingredient under clinical evaluation.
Thursday, October 03, 2013
FDA Performs Re-inspection of AMRI Burlington MA Facility
Issues Form 483 for three inspectional observations.
Friday, July 26, 2013
AMRI Burlington Receives DEA Approval to Handle Controlled Substances
Approval to handle Schedule 2 and 2N controlled substances at this location further supports AMRI SMARTSOURCING™ offering.
Wednesday, June 19, 2013
AMRI Promotes Susan Collins to Director, Business Development
Ms. Collins is responsible for leading AMRI’s North American Discovery Business Development team.
Tuesday, June 18, 2013
AMRI Announces Appointment of Chairman of the Board of Directors
Company has appointed William S. Marth as Chairman of the Board, effective June 5, 2013.
Friday, June 07, 2013
AMRI and Ono Broaden SMARTSOURCING™ Collaboration
New agreement extends drug discovery and development collaboration between the companies.
Friday, April 26, 2013
AMRI Announces Five-Year Extension of API Supply Agreement with Shire
AMRI enters into a multi-year supply agreement for an undisclosed product.
Tuesday, October 23, 2012
AMRI Promotes Daniel Conlon to Senior Director of Business Development
Conlon will lead AMRI’s development and manufacturing services sales team for North America.
Wednesday, September 12, 2012
Scientific News
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!